natgillin/translations-raw huggingface dataset:
Therefore patients should remain under close clinical observation by physicians experienced in the treatment of these associated HIV diseases. 
Stoga te bolesnike treba pažljivo nadzirati liječnik koji ima iskustva u liječenju HIV infekcija.
In a meta-analysis of five clinical trials where abacavir was added to intensify therapy, of 166 subjects, 123 (74%) had M184V/I, 50 (30%) had T215Y/F, 45 (27%) had M41L, 30 (18%) had K70R and 25 (15%) had D67N. 
U metaanalizi 5 kliničkih ispitivanja u kojima je abakavir dodan kako bi se pojačala terapija, od 166 ispitanika, 123 (74%) je imalo M184V/I, 50 (30%) je imalo T215Y/F, 45 (27%) je imalo M41L, 30 (18%) je imalo K70R, a 25 (15%) je imalo D67N.
Long term data with abacavir used as a once daily regimen (beyond 48 weeks) are currently limited. 
Zasad nema dovoljno podataka o dugoročnoj primjeni abakavira u doziranju jedanput na dan (dulje od 48 tjedana).
• development of 1 or more symptom from at least 2 of the following groups: - Fever - Shortness of breath, sore throat or cough - Nausea or vomiting or diarrhoea or abdominal pain - Extreme tiredness or achiness or general ill feeling 
• razvoja 1 ili više simptoma iz najmanje 2 od sljedećih grupa: - vrućica - kratkoća daha, grlobolja ili kašalj
Clinical relevance in human of these data is unknown. 
Klinički značaj tih podataka za ljude nije poznat.
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4). 
Zabilježeno je da se autoimuni poremećaji (kao što je Gravesova bolest i autoimuni hepatitis) javljaju kod imunološke reaktivacije, međutim, zabilježeno vrijeme početka je varijabilno i ovi se događaji mogu javiti mnogo mjeseci nakon početka liječenja (vidjeti dio 4.4).
If you cannot swallow the tablet(s), you may crush and combine them with a small amount of food or drink, and take all the dose immediately. 
Ako ne možete progutati tabletu, možete je izdrobiti i pomiješati s malom količinom hrane ili pića, te uzeti odmah cijelu dozu.
Children receiving abacavir oral tablets according to the recommended dosage regimen achieve higher plasma abacavir exposure than children receiving oral solution because higher mg/kg doses are administered with the tablet formulation. 
Djeca koja primaju tablete abakavira za peroralnu primjenu sukladno preporučenom režimu doziranja postižu više razine izloženosti abakaviru u plazmi nego djeca koja primaju oralnu otopinu jer se tabletama primjenuju veće doze u mg/kg.
These findings included decreased foetal body weight, foetal oedema, and an increase in skeletal variations/malformations, early intra-uterine deaths and still births. 
Ovi nalazi uključuju smanjenu fetalnu tjelesnu težinu, fetalni edem i porast varijacija/malformacija kostura, rane intrauterine smrti i mrtvorođenčad.
If you have any further questions ask your doctor or pharmacist. 
Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
The bottle contains 240 ml (20 mg abacavir/ml) of solution. 
Boca sadrži 240 ml (20 mg abakavira/ml) otopine.
Isolates from most patients experiencing virological failure with a regimen containing abacavir in pivotal clinical trials showed either no NRTI-related changes from baseline (45%) or only M184V or M184I selection (45%). 
Izolati većine bolesnika iz ključnih kliničkih ispitivanja, u kojih je uz terapiju koja sadržava abakavir izostao virološki odgovor, pokazali su ili nikakav pomak od početnih vrijednosti povezan s NRTI (45%) ili samo selekciju M184V ili M184I (45%).
The recommended dose is 8 mg/kg twice a day or 16 mg/kg once a day, up to a maximum total daily dose of 600 mg daily. 
Preporučena doza je 8 mg/kg dvaput na dan ili 16 mg/kg jedanput na dan, do maksimalne ukupne doze od 600 mg na dan.
In a crossover study in 27 HIV-infected patients, intracellular carbovir-TP exposures were higher for the abacavir 600 mg once daily regimen (AUC24,ss + 32 %, Cmax24,ss + 99 % and Ctrough + 18 %) compared to the 300 mg twice daily regimen. 
U križnoj studiji 27 bolesnika zaraženih virusom HIV unutarstanična izloženost karbovir-TP-u bila je veća pri doziranju od 600 mg abakavira jedanput na dan (AUC24,ss + 32%, Cmax24,ss + 99% i Ctrough + 18%) u usporedbi s 300 mg dvaput na dan.
Medicinal product subject to restricted medical prescription (See Annex I Summary of Product Characteristics, 4.2). 
Lijek se izdaje na ograničeni recept (Vidjeti Prilog I.: Sažetak opisa svojstava lijeka, dio 4.2).
There was a low, similar overall incidence of virologic failure (viral load >50 copies/ml) in both the once and twice daily treatment groups (10% and 8% respectively). 
Zabilježena je mala ukupna incidencija izostanka virološkog odgovora (virusno opterećenje > 50 kopija/ml), slična u obje skupine (10% u skupini liječenoj jedanput na dan i 8% u skupini liječenoj dvaput na dan).
How to take Ziagen 
Kako uzimati Ziagen
• In order to avoid restarting abacavir, patients who have experienced a suspected HSR should be instructed to dispose of their remaining Ziagen tablets 
• Kako bi se izbjeglo ponovno uzimanje abakavira, bolesnike koji su imali suspektnu reakciju preosjetljivosti mora se uputiti da zbrinu preostale Ziagen tablete.
It is important to take Ziagen regularly, because if you take it at irregular intervals, you may be more likely to have a hypersensitivity reaction. 
Važno je da Ziagen uzimate redovito jer neredovito uzimanje može povećati rizik od reakcije preosjetljivosti.
For example, if your dose is 30 ml, you need to take 3 syringe-fulls of medicine Take the syringe out of the bottle and wash it thoroughly in clean water. 
Na primjer, ako doza iznosi 30 ml, morate uzeti 3 pune štrcaljke lijeka.
ViiV Healthcare BV, Huis ter Heideweg 62, 3705 LZ Zeist, Netherlands 
ViiV Healthcare BV, Huis ter Heideweg 62, 3705 LZ Zeist, Nizozemska
In a pharmacokinetic study (PENTA 15), four virologically controlled subjects less than 12 months of age switched from abacavir plus lamivudine oral solution twice daily to a once daily regimen. 
U jednom je farmakokinetičkom ispitivanju (PENTA 15) četvero ispitanika mlađih od 12 mjeseci s kontroliranim virusnim opterećenjem bilo prebačeno s oralne otopine abakavir plus lamivudin dvaput na dan na režim doziranja jedanput na dan.
Changes in laboratory chemistries 
Promjene u laboratorijskim nalazima biokemijskih parametara
The results are summarised in the table below: 
Rezultati su sažeto prikazani u sljedećoj tablici:
Importantly, such symptoms may lead to misdiagnosis of HSR as respiratory disease (pneumonia, bronchitis, pharyngitis), or gastroenteritis . 
Važno je napomenuti da takvi simptomi mogu dovesti do pogrešne dijagnoze reakcije preosjetljivosti kao bolesti dišnog sustava (pneumonije, bronhitisa, faringitisa) ili gastroenteritisa.
• a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis) 
• široko rasprostranjen osip sa žuljevima i ljuštenjima kože, posebice oko usta, nosa, očiju i genitalija (Stevens-Johnsonov sindrom) i u težim oblicima koji uzrokuju ljuštenje kože u više od
Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk of severe and potentially fatal hepatic adverse reactions. 
Bolesnici koji su kronični nositelji virusa hepatitisa B ili C i koji su na kombinacijskoj antiretrovirusnoj terapiji imaju povećan rizik od nastupa ozbiljnih i potencijalno fatalnih jetrenih nuspojava.
Children from one year of age: The recommended dose is 8 mg/kg twice daily or 16 mg/kg once daily, up to a maximum total daily dose of 600 mg (30 ml). 
Djeca od navršenih godinu dana: Preporučena doza je 8 mg/kg dvaput na dan ili 16 mg/kg jedanput na dan, do maksimalne ukupne dnevne doze od 600 mg (30 ml).
As well as the side effects listed below for Ziagen, other conditions can develop during combination therapy for HIV. 
Kao i niže navedene nuspojave za Ziagen, za vrijeme kombinirane terapije za HIV mogu se razviti i druga stanja.
According to clinical trials performed in children abacavir is rapidly and well absorbed from oral solution and tablet formulations administered to children. 
Klinička ispitivanja provedena s djecom pokazala su da se abakavir brzo i dobro apsorbira nakon primjene oralne otopine i tablete u djece.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON - TABLETS 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKA KARTONSKA KUTIJA - TABLETE
Following multiple oral doses of abacavir 300 mg twice a day there is no significant accumulation of abacavir. 
300 mg dvaput na dan nije bilo značajnog nakupljanja abakavira.
Children receiving abacavir oral solution according to the recommended dosage regimen achieve plasma abacavir exposure similar to adults. 
Djeca koja primaju oralnu otopinu abakavira sukladno preporučenom režimu doziranja postižu sličnu razinu izloženosti abakaviru kao i odrasli.
Children weighing ≥ 20 kg to < 25 kg: The recommended dose is 450 mg daily. 
Djeca tjelesne težine od ≥ 20 kg do < 25 kg: Preporučena doza je 450 mg na dan.
Pains in the joints or muscles, swelling of the neck, shortness of breath, sore throat, cough, occasional headaches, inflammation of the eye (conjunctivitis), mouth ulcers, low blood pressure, tingling or numbness of the hands or feet. 
Bolove u zglobovima ili mišićima, oticanje vrata, nedostatak zraka, grlobolju, kašalj, povremene glavobolje, upalu oka (konjunktivitis), vrijedovi u ustima, nizak krvni tlak, trnce ili utrnulost šaka ili stopala.
• if you are allergic (hypersensitive) to abacavir (or any other medicine containing abacavir - such as Triumeq, Trizivir or Kivexa) or any of the other ingredients of this medicine (listed in Section 6) 
• ako ste alergični (preosjetljivi) na abakavir (ili bilo koji lijek koji sadržava abakavir npr. Triumeq, Trizivir ili Kivexa), ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.)
Ziagen can be taken with or without food. 
Ziagen možete uzimati s ili bez hrane.
Methadone: in a pharmacokinetic study, co-administration of 600 mg abacavir twice daily with methadone showed a 35% reduction in abacavir Cmax and a one hour delay in tmax but the AUC was unchanged. 
U farmakokinetičkom ispitivanju istodobna primjena 600 mg abakavira dvaput na dan i metadona rezultirala je 35% smanjenjem Cmax abakavira i odgađanjem tmax za jedan sat, ali je AUC ostao nepromijenjen.
The study Data Safety Monitoring Board stopped the ZDV/3TC/ABC arm at this time based on the higher proportion of patients with virologic failure. 
U tom trenutku je studijski odbor za prikupljanje podataka o sigurnosti primjene prekinuo liječenje u skupini koja je uzimala ZDV/3TC/ABC zbog višeg udjela bolesnika s virološkim neuspjehom.
Similar clinical success (point estimate for treatment difference -1.7, 95% CI -8.4, 4.9) was observed for both regimens. 
U oba režima liječenja zabilježen je sličan klinički uspjeh (ocijenjena razlika liječenja: -1,7; 95% CI -8,4; 4,9).
There have been reports of mitochondrial dysfunction in HIVnegative infants exposed in utero and/or post-natally to nucleoside analogues (see section 4.4). 
Prijavljena je mitohondrijska disfunkcija u HIV negativne novorođenčadi izložene analozima nukleozida in utero i/ili nakon rođenja (vidjeti dio 4.4).
Pancreatitis has been reported, but a causal relationship to abacavir treatment is uncertain. 
Zabilježen je pankreatitis, ali nije sigurna uzročna povezanost s liječenjem abakavirom.
You must carefully read all the information under ‘Hypersensitivity reactions' in the panel in Section 4. 
Morate pažljivo pročitati sve informacije u okviru “Reakcije preosjetljivosti” u dijelu 4.
Those studied were mainly antiretroviral experienced patients. 
Te su studije najvećim dijelom promatrale bolesnike koji su primali do tada antiretrovirusnu terapiju.
The usual dose of Ziagen is 600 mg a day. 
Uobičajena doza lijeka Ziagen je 600 mg na dan.
1206 HIV-infected paediatric patients aged 3 months to 17 years were enrolled in the ARROW Trial (COL105677), 669 of whom received abacavir and lamivudine either once or twice daily (see section 5.1). 
U ispitivanje ARROW (COL105677) bilo je uključeno 1206 HIV-om zaraženih pedijatrijskih bolesnika u dobi od 3 mjeseca do 17 godina, među kojima je njih 669 primalo abakavir i lamivudin jedanput ili dvaput na dan (vidjeti dio 5.1).
Children from 3 months of age weighing less than 25 kg 
Djeca od navršena 3 mjeseca tjelesne težine manje od 25 kg
No dosage adjustment of Ziagen is necessary in patients with renal dysfunction. 
Nije potrebno prilagođavati dozu lijeka Ziagen u bolesnika s poremećajem funkcije bubrega.
Since Ziagen contains abacavir some patients taking Ziagen may develop a hypersensitivity reaction (serious allergic reaction) which can be life-threatening if treatment with Ziagen is continued. 
Budući da Ziagen sadrži abakavir, neki bolesnici koji uzimaju Ziagen mogu razviti reakciju preosjetljivosti (ozbiljnu alergijsku reakciju) koja može biti opasna po život ako se nastavi sa uzimanjem lijeka Ziagen.
Abacavir is associated with a risk for hypersensitivity reactions (HSR) (see section4.8) characterised by fever and/or rash with other symptoms indicating multi-organ involvement. 
Reakcije preosjetljivosti (vidjeti i dio 4.8) Abakavir se povezuje s rizikom od reakcija preosjetljivosti (vidjeti dio 4.8), koje karakteriziraju vrućica i/ili osip praćeni drugim simptomima koji upućuju na zahvaćenost većeg broja organa.
In the small sample size for genotypic analysis, there was a trend toward a higher rate of NRTI-associated mutations in the once daily versus the twice daily abacavir regimens. 
U malom uzorku za genotipsku analizu zabilježen je trend prema većoj stopi mutacija povezanih s NRTI pri doziranju abakavira jedanput na dan u odnosu na doziranje dvaput na dan.
The malformative risk is unlikely in humans based on those data. 
S obzirom na te podatke, rizik od malformacija u ljudi nije vjerojatan.
Don't push too hard and squirt the liquid into the back of your throat, or you may choke Repeat steps 3 to 7 in the same way until you have taken your whole dose. 
Nemojte gurati prejako niti špricati otopinu u stražnju stranu grla jer bi moglo doći do gušenja.
Ziagen oral solution also contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions (possibly delayed). 
Ziagen oralna otopina također sadrži metilparahidroksibenzoat i propilparahidroksibenzoat koji mogu uzrokovati alergijsku reakciju (moguće i reakcije odgođene preosjetljivosti).
In a study of 20 HIV-infected patients receiving abacavir 300 mg twice daily, with only one 300 mg dose taken prior to the 24 hour sampling period, the geometric mean terminal carbovir-TP intracellular half-life at steady-state was 20.6 hours, compared to the geometric mean abacavir plasma half-life in this study of 2.6 hours. 
U ispitivanju 20 bolesnika zaraženih virusom HIV, koji su primali abakavir u dozi od 300 mg dvaput na dan, pri čemu su jednu dozu od 300 mg uzeli prije 24-satnog razdoblja uzimanja uzoraka, geometrijsko srednje terminalno unutarstanično poluvrijeme karbovir-TP-a u stanju dinamičke ravnoteže iznosilo je 20,6 sati, u usporedbi s geometrijskim srednjim poluvremenom abakavira u plazmi od 2,6 sati.
If you forget to take Ziagen 
Ako ste zaboravili uzeti Ziagen
In PENTA 15 study, the geometric mean plasma abacavir AUC(0-24) (95% CI) of the four subjects under 12 months of age who switch from a twice daily to a once daily regimen (see section 5.1) are 15.9 (8.86, 28.5) µg.h/ml in the once-daily dosing and 12.7 (6.52, 24.6) µg.h/ml in the twice-daily dosing. 
U ispitivanju PENTA 15, geometrijska srednja vrijednost AUC(0-24) abakavira u plazmi (95% CI) u četiri ispitanika mlađa od 12 mjeseci koja su s režima primjene dvaput na dan prešla na režim primjene jedanput na dan (vidjeti dio 5.1) iznosila je 15,9 (8,86; 28,5) µg.h/ml uz doziranje jedanput na dan te 12,7 (6,52; 24,6) µg.h/ml uz doziranje dvaput na dan.
Similarly, greater proportions of children treated with the abacavir containing combinations had HIV-1 RNA ≤50 copies/ml at 48 weeks (53%, 42% and 28% respectively, p=0.07). 
Slično tome, veći udjeli djece liječene kombinacijama koje su sadržavale abakavir imali su HIV-1 RNK ≤50 kopija/ml u 48. tjednu (53%, 42% odnosno 28%, p=0,07).
• Ziagen must be stopped without delay, even in the absence of the HLA-B*5701 allele, if an HSR is suspected. 
• Liječenje lijekom Ziagen mora se bez odlaganja prekinuti, čak i u odsustvu alela HLA-B*5701, ako se posumnja na reakciju preosjetljivosti.
TAMs might be selected when thymidine analogs are associated with abacavir. 
Do selekcije mutacije analoga timidina može doći kad su analozi timidina povezani s abakavirom.
If abacavir is used in patients with mild hepatic impairment, then close monitoring is required, including monitoring of abacavir plasma levels if feasible (see sections 4.4 and 5.2). 
Bolesnike s blagim oštećenjem jetre koji koriste abakavir potrebno je pažljivo pratiti, uključujući praćenje razine abakavira u plazmi, ako je moguće (vidjeti dijelove 4.4 i
Glaxo Operations UK Ltd (trading as GlaxoWellcome Operations) Harmire Road 
Glaxo Operations UK Ltd (posluje kao Glaxo Wellcome Operations) Harmire Road
Phenotypic resistance to abacavir requires M184V with at least one other abacavir-selected mutation, or M184V with multiple TAMs. 
Za fenotipsku rezistenciju na abakavir potrebna je mutacija M184V uz najmanje još jednu abakavirom uzrokovanu mutaciju, ili mutacija M184V s višestrukim mutacijama analoga timidina.
Twice daily (300 mg) administration: 
Primjena dvaput na dan (300 mg):
1206 paediatric patients aged 3 months to 17 years enrolled in the ARROW Trial (COL105677) and were dosed according to the weight - band dosing recommendations in the World Health Organisation treatment guidelines (Antiretroviral therapy of HIV infection in infants and children, 2006). 
U ispitivanje ARROW (COL105677) bilo je uključeno 1206 pedijatrijskih bolesnika u dobi od 3 mjeseca do 17 godina, kojima su se lijekovi dozirali sukladno preporukama za doziranje prema tjelesnoj težini, objavljenima u smjernicama za liječenje Svjetske zdravstvene organizacije (Antiretrovirusna terapija za dojenčad i djecu zaraženu HIV-om, 2006.).
The mean (CV) AUC over a dosing interval of 12 hours was 6.02 µg.h/ml (29%), equivalent to a daily AUC of approximately 12.0 µg.h/ml. 
Srednja vrijednost AUC-a tijekom intervala doziranja od 12 sati iznosi 6,02 µg.h/ml (koeficijent varijacije 29%), što odgovara dnevnom AUC-u od oko 12 µg.h/ml.
Contains amongst others: sorbitol (340 mg/ml, E420), methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216). 
Također sadrži: sorbitol (340 mg/ml, E420), metilparahidroksibenzoat (E218) i propilparahidroksibenzoat (E216).
The results showed that there was a mean (90%CI) increase of 1.89 fold [1.32; 2.70] in the abacavir AUC, and 1.58 [1.22; 2.04] fold in the elimination half-life. 
Rezultati su pokazali prosječan (90% CI) porast AUC-a abakavira za 1,89 puta [1,32; 2,70], te produljenje poluvremena za 1,58 puta [1,22; 2,04].
The pharmacokinetics of abacavir have been studied in patients with mild hepatic impairment (Child-Pugh score 5-6) receiving a single 600 mg dose ; the median (range) AUC value was 24.1 (10.4 to 54.8) ug.h/ml. 
Farmakokinetika abakavira ispitivana je u bolesnika s blagim oštećenjem jetre (Child-Pugh vrijednost 5-6) koji su primili jednokratnu dozu od 600 mg; medijan (raspon) AUC vrijednosti bio je 24,1 (10,4 do 54,8) ug.h/ml.
Other symptoms include: 
Ostali simptomi uključuju:
Remove the syringe from the adapter Put the syringe into your mouth, placing the tip of the syringe against the inside of your cheek. 
Stavite štrcaljku u usta, tako da vrh štrcaljke dodiruje unutrašnju stranu obraza.
Metabolism and nutrition disorders Common: anorexia Very rare: lactic acidosis 
Često: anoreksija Vrlo rijetko: laktacidoza
ABC HSR and expand on the information already included in the currently approved EU SPC: 
Ključne poruke uključene u edukacijske materijale kako bi se poboljšalo razumijevanje i povećala svijest o ABC HSR i proširile informacije već uključene u trenutno odobreni EU SPC:
Take special care with Ziagen 
Budite posebno oprezni s lijekom Ziagen
HLA-B*5701 status must always be documented and explained to the patient prior to initiating therapy. 
HLAB*5701status mora uvijek biti dokumentiran i objašnjen bolesniku prije početka liječenja.
In adults treated with abacavir in combination with lamivudine and zidovudine the proportion of patients with undetectable viral load (<400 copies/ml) was approximately 70% (intention to treat analysis at 48 weeks) with corresponding rise in CD4 cells. 
U odraslih bolesnika liječenih abakavirom u kombinaciji s lamivudinom i zidovudinom, udio bolesnika s virusnim opterećenjem ispod razine detekcije (<400 kopija/ml) bio je oko 70% (analiza bolesnika s namjerom liječenja nakon 48 tjedana), uz odgovarajući porast broja CD4 stanica.
Ziagen contains the active ingredient abacavir. 
Ziagen sadrži djelatnu tvar abakavir.
This can be taken either as 300 mg (15 ml) twice a day or 600 mg (30 ml) once a day. 
Ona se može uzeti po 300 mg (15 ml) dvaput na dan ili 600 mg (30 ml) jedanput na dan.
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment. 
Zabilježeno je da se autoimuni poremećaji (npr Gravesova bolest i autoimuni hepatitis) javljaju kod imunološke reaktivacije, međutim, zabilježeno vrijeme početka je varijabilno i ovi se događaji mogu javiti mnogo mjeseci nakon početka liječenja.
Anyone taking Ziagen could develop a hypersensitivity reaction to abacavir, which could be life threatening if they continue to take Ziagen. 
Svatko tko uzima Ziagen može razviti reakciju preosjetljivosti na abakavir koja može ugroziti život bolesnika, ako nastavi uzimati Ziagen.
Any two NRTIassociated mutations Any three NRTIassociated mutations Four or more NRTIassociated mutations 
Bilo koja pojedinačna mutacija NRTI Bilo koje dvije mutacije povezane s NRTI Bilo koje tri mutacije povezane s NRTI
In a separate study comparing the unblinded NRTI combinations (with or without blinded nelfinavir) in children, a greater proportion treated with abacavir and lamivudine (71%) or abacavir and zidovudine (60%) had HIV-1 RNA ≤400 copies/ml at 48 weeks, compared with those treated with lamivudine and zidovudine (47%)[ p=0.09, intention to treat analysis]. 
U zasebnom ispitivanju, u kojem su se uspoređivale otvorene kombinacije NRTI-ja (sa slijepim nelfinavirom ili bez njega) u djece, veći udio bolesnika liječenih abakavirom i lamivudinom (71%) ili abakavirom i zidovudinom (60%) imalo je razinu HIV-1 RNK ≤ 400 kopija/ml nakon 48 tjedana u usporedbi s onima koji su primali kombinaciju lamivudina i zidovudina (47%) [p=0,09, u analizi bolesnika s namjerom liječenja].
Proportions with HIV-1 RNA < 50 copies/ml (50% versus 47%) and < 400 copies/ml (54% versus 57%) were also similar in each group (ITT population). 
kopija/ml (50% naspram 47%), te onih s < 400 kopija/ml (54% naspram 57%).
In the as treated (AT) analysis the difference between both treatment arms was more noticeable (88% of patients in the abacavir group, compared to 95% of patients in the zidovudine group (point estimate for treatment difference: -6.8, 95% CI11.8; -1.7). 
U analizi svih liječenih bolesnika razlika između dva režima liječenja bila je još izraženija (88% bolesnika koji su uzimali abakavir, te 95% bolesnika koji su uzimali zidovudin (ocijenjena razlika liječenja: -6,8; 95% CI -11,8; -1,7).
Summary of Stead-State Plasma Abacavir AUC (0-24) (µg.h/ml) and Statistical Comparisons for Once and Twice-Daily Oral Administration Across Studies 
Sažetak plazmatske vrijednosti AUC(0-24) (µg.h/ml) abakavira u stanju dinamičke ravnoteže i statističke usporedbe peroralne primjene jedanput na dan u odnosu na primjenu dvaput na dan u svim ispitivanjima